These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25651523)

  • 1. Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches.
    Small DS; Ke AB; Hall SD; Mantlo N; Rotelli M; Friedrich S
    J Clin Pharmacol; 2015 Jul; 55(7):757-67. PubMed ID: 25651523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
    Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
    Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia.
    Borghi C; Cicero AF
    Expert Opin Drug Metab Toxicol; 2017 Feb; 13(2):205-209. PubMed ID: 27852117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects.
    Small DS; Royalty J; Cannady EA; Hale C; Wang MD; Downs D; Suico JG
    Pharmacotherapy; 2016 Jul; 36(7):749-56. PubMed ID: 27284735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evacetrapib at a supratherapeutic steady state concentration does not prolong QT in a thorough QT/QTc study in healthy participants.
    Suico JG; Friedrich S; Krueger KA; Zhang W
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):283-9. PubMed ID: 24271137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
    Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):543-9. PubMed ID: 24737712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
    Gotto AM; Cannon CP; Li XS; Vaidya S; Kher U; Brinton EA; Davidson M; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    Am J Cardiol; 2014 Jan; 113(1):76-83. PubMed ID: 24188894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice.
    Hartmann G; Kumar S; Johns D; Gheyas F; Gutstein D; Shen X; Burton A; Lederman H; Lutz R; Jackson T; Chavez-Eng C; Mitra K
    Drug Metab Dispos; 2016 Mar; 44(3):428-34. PubMed ID: 26712818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State.
    Small DS; Zhang W; Royalty J; Cannady EA; Downs D; Friedrich S; Suico JG
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):483-9. PubMed ID: 25736283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Garg A; Panebianco D; Cote J; Bergman AJ; Van Hoydonck P; Laethem T; Van Dyck K; Chen J; Chavez-Eng C; Archer L; Lutz R; Hilliard D; Snyder K; Jin B; Van Bortel L; Lasseter KC; Al-Huniti N; Dykstra K; Gottesdiener K; Wagner JA
    Br J Clin Pharmacol; 2009 Oct; 68(4):535-45. PubMed ID: 19843057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
    Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
    Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case.
    Johns DG; Wang SP; Rosa R; Hubert J; Xu S; Chen Y; Bateman T; Blaustein RO
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00543. PubMed ID: 31832204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination.
    Krishna R; Gheyas F; Liu Y; Hagen DR; Walker B; Chawla A; Cote J; Blaustein RO; Gutstein DE
    Clin Pharmacol Ther; 2017 Nov; 102(5):832-840. PubMed ID: 28380664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes.
    Johns DG; LeVoci L; Krsmanovic M; Lu M; Hartmann G; Xu S; Wang SP; Chen Y; Bateman T; Blaustein RO
    Drug Metab Dispos; 2019 Mar; 47(3):227-233. PubMed ID: 30567880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome.
    Cannady EA; Suico JG; Wang MD; Friedrich S; Rehmel JR; Nicholls SJ; Krueger KA
    Br J Clin Pharmacol; 2015 Dec; 80(6):1388-98. PubMed ID: 26264702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
    Lauring B; Liu Y; Li XS; Larson P; Moreau A; Farmer HF; Johnson-Levonas AO; Wagner JA; Lai E
    J Clin Pharmacol; 2014 Jul; 54(7):765-75. PubMed ID: 24615657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.